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Precision medicine requires markers for therapeutic guidance. The purpose of this study was to determine whether epithelial
ovarian cancer (EOC) epigenetics can lead to the identification of biomarkers for precision medicine. Through integrative meth-
ylomics, we discovered and validated the epigenetic signature of NEFH and HS3ST2 as an independent prognostic factor for
type II EOC in our dataset (n584), and two independent methylomics datasets (total n5467). Integrated transcriptomics
dataset (n51147) and tissue microarrays (n554) of HS3ST2 also related to high-methylation statuses and the EOC progno-
sis. Mechanistic explorations of HS3ST2 have assessed responses to oncogenic stimulations such as IL-6, EGF, and FGF2 in
cancer cells. The combination of HS3ST2 and various oncogenic ligands also confers the worse outcome. 3-O-sulfation of hep-
aran sulfate by HS3ST2 makes ovarian cancer cells intrinsically sensitive to oncogenic signals, which sheds new light on the
application of HS3ST2 as a companion diagnostic for targeted therapy using kinase inhibitors or therapeutic antibodies.
Epithelial ovarian cancer (EOC) is one of the most lethal gyne-
cological cancers. Patients with vague symptoms are often diag-
nosed at advanced stages. The standard treatment for EOC is
primary surgery followed by platinum-based chemotherapy.1
Over the past three decades, the five-year survival rate has been
<40% and has not significantly improved.2 The development
of novel therapeutics is urgently needed.3 Recently, the molecu-
lar classification of type I and type II EOC was proposed.4 The
identification of biomarkers will facilitate the individualized
treatment of patients and the development of precision
medicine.
The development of new therapeutics for EOC is increas-
ing, but success has been limited. There has been high hope
in the field of EOC treatment for demethylation agents, such
as decitabine and azacitidine, which are approved for myelo-
dysplastic syndrome in a subset of leukemias.5 These epige-
netic drugs can sensitize platinum-resistant ovarian cancer
cells to commonly used drugs in vitro, in preclinical models
and in early-phase clinical trials.6,7 However, we have not yet
obtained more promising results in the phase II clinical trial.8
Targeted therapies such as EGFR kinase inhibitors and thera-
peutic antibodies have been successful in many cancers9, but
not in ovarian cancer.10 PI3K/Akt/mTOR pathway inhibitors
and IL-6 neutralizing antibodies were once thought promis-
ing for EOC treatment but all have failed in clinical trials.11,12
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Bevacizumab, an anti-VEGF antibody, is the targeted thera-
peutic that has marginal benefit and is FDA approved for
EOC.13 The immune checkpoint inhibitors that are successful
in melanoma, lung cancer, kidney cancer and bladder cancer
had only at best a 15% response rate in ovarian cancer in a
phase II trial.14 Although the recent FDA approval of a
PARP inhibitor without the need for BRCA1/2 mutation
testing is encouraging, there is still a need for biomarkers to
stratify patients for future clinical trials of targeted therapies
in ovarian cancer.15
Epigenetic change is pervasive in almost every aspect of can-
cer development. Epigenetic changes, including DNA methyla-
tion, histone modification, nucleosome remodeling and non-
coding RNAs, are heritable changes in gene expression without
alterations in the DNA sequence itself.16 Abnormal DNA
methylation occurs during tumorigenesis and is maintained in
offspring cells, possibly leaving relics of carcinogenesis. Abnor-
mal DNA methylation may serve as a biomarker for early
detection, outcome prediction, and individualized treatment.17
Hypermethylation of several genes, including those involved in
DNA repair18, AKT/mTOR19, redox19, apoptosis20, cell
adhesion21 and cancer stem cell signaling pathways22,23, was
reported to correlate with poor prognosis in ovarian cancer
patients. Those epigenetics signatures revealed EOC heteroge-
neity and prognostic carcinogenesis that probably initiate by
the diversity of genetic mutations.4 However, the prognostic
value of only a few genes was validated using independent
sets.19,20,22 The silencing of tumor suppressor genes that inhibit
multiple oncogenic pathways is common in cancer, which may
suggest a differential therapeutic response to targeted thera-
pies.24 Thus, DNA methylation may be a potential factor by
which to stratify ovarian cancer patients who need further
therapy.
The aim of this study was to investigate the clinical signifi-
cance of EOC methylomics. We found a methylation signature
for poor outcome and revealed that epigenetic loss of 3-O sulfa-
tion of heparan sulfate (HS) might sensitize EOC to various
oncogenic signaling pathways.
Material and Methods
Patient samples
A total of 115 patients were diagnosed with advanced-stage
EOC between March 2000 and June 2013 at the Tri-Service
General Hospital (TSGH) in Taipei, Taiwan. The inclusion
criteria stipulated that study participants must be female and
aged 20 to 85 years. Other inclusion and exclusion criteria
and the stored tissues are described in detail elsewhere.25
Age, histological type, International Federation of Gynecology
and Obstetrics (FIGO) stage, histological grade, and survival
status were obtained from the patients’ hospital records. The
samples size was predicted for epigenomics analyses which
accorded to 0.2 of differential means in long-term and short-
term of three-year overall survival (OS) groups, 0.175 of stan-
dard deviations in two groups, 0.05 of type I error (a), 0.2 of
type II error (b, 1-power), and 1.5 ratio of two groups. The
total samples size was predicted as twenty-seven, and we
added two samples in two groups for avoiding some tissue
DNA may unqualified. Therefore, we randomly selected half
the samples (n5 31) collected between 2000 and 2008 for
epigenomics analyses by methylation beadchip in the discov-
ery phase studies. The remaining 84 samples composed an
independent set in the validation phase studies. Demographic
and clinical data are provided in Table S1, Supporting Infor-
mation. Studies were conducted and tissue samples were
from tissue bank with approval from the Institutional Review
Board of the TSGH and in accordance with the Declaration
of Helsinki.
Analysis of methylomics data
To select candidate genes, genome-wide methylation profiles
were screened with the Infinium HumanMethylation27 Bead-
Chip (Illumina, San Diego, CA, USA), which includes 27,578
CpG sites corresponding to 14,475 genes. Methylomics data
were background normalized, yielding 20,022 probes with
effective detection (the detecting P values 0.001). Patients
were dichotomized as short or long survivors based on sur-
vival for less than or more than three years since first therapy
after diagnosis of ovarian cancer. We selected sites with sig-
nificantly different methylation based on the two-tailed t test
(P 0.01) and a difference >20% (in an absolute difference
of AVG-b value 0.2, Fig. S1A, Supporting Information). To
assess the significant risk related to follow up time, we
converted AVG-b values into a binary code to create a uni-
variate Cox proportional hazard model. An AVG-b value
of 0.4 was set to 1, and a value of <0.4 was set to 0. Based
on our assumptions, we selected probes with P< 0.01 and
HR 2 (Figs. S1B and S1C, Supporting Information).
What’s new?
Most targeted therapies for epithelial ovarian cancer are ineffective. For precision medicine to be effective, companion diag-
nostic tests are needed. Through integrative epigenomics, here the authors discovered and validated the epigenetic signature
of NEFH/HS3ST2 as a stratifying prognostic factor. Mechanistic investigations of HS3ST2 revealed inhibitory effects on various
oncogenic signals and malignant phenotypes. Low HS3ST2 and overexpression of oncogenic ligands synergized to confer a
poor outcome. Furthermore, 3-O-sulfation of heparan sulfate by HS3ST2 made ovarian cancer cells intrinsically sensitive to
oncogenic signals, suggesting the application of HS3ST2 as a companion diagnostic for targeted therapy using kinase inhibi-
tors or therapeutic antibodies.
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To validate the prognostic relevance, we used two public
methylation datasets, the The Cancer Genome Atlas (TCGA)
and Australian Ovarian Cancer Study (AOCS) datasets. In
the TCGA dataset, we selected 387 of 490 samples with com-
plete clinical data and diagnosis of advanced-stage and G2/
G3 serous ovarian carcinoma to perform a Kaplan-Meier
analysis. All data were downloaded from the TCGA Data
Portal and normalized to the background control. The 95th
percentile of methylation was set as the cutoff point; higher
values were defined as high methylation, and lower values
indicated low methylation. We downloaded the AOCS data-
set from GEO based on the accession ID GSE65820 and
selected the primary tumor data. The death, recurrent and
late follow-up dates were released from the International
Cancer Genome Consortium data portal and excluded data
annotated with disease progression status.
Cell lines and culture conditions
The human EOC cell lines CP70, OVCAR3, and SKOV3 and
immortalized normal cells (IOSE) were purchased or
obtained from previously described sources.26,27. The Kura-
mochi (JCRB0098) were purchased from the Japanese Collec-
tion of Research Bioresources (JCRB) Cell Bank. Kuramochi
cells was cultured in RPMI-1640 (Invitrogen Thermo Fisher
Scientific, Waltham, MA, USA) and 10% standard FBS. All
cell lines underwent identity verification by DNA profiling of
short tandem repeat (STR) sequences by MISSION BIO-
TECH (Taipei, Taiwan) and STR information on available in
NCBI Biosample websites.
Tissue microarray and immunohistochemistry
The tissue microarray (TMA) were constructed with paraffin-
embedded tumor tissues from the Department of Pathology,
National Defense Medical Centre, Taipei, Taiwan.28 Fifty
advanced-stage ovarian surface epithelial carcinomas and
four borderline tumors with available demographic informa-
tion are described in Table S2, Supporting Information; these
samples were evaluated for HS3ST2 protein expression using
a rabbit polyclonal antibody to HS3ST2 (1:1000 dilution,
ab155777, Abcam, Cambridge, London, UK). The protein
level in the TMA samples was scored by two pathologists,
and the expression score had calculated the product of the
intensity and the area of positive tumor cells. The intensity
was scored as 0 (no staining), 1 (weak), 2 (moderate), or 3
(strong). The area of positive tumor cells was scored from 0
(< 10% of the counted cells) to 100 (all positive). Pathologi-
cal data on each specimen examined were collected following
an Institutional Review Board-approved protocol.
Western blots
Western blots were used to explore candidate proteins in
total cell lysates and described details in the supplementary
methods and materials (see supplementary information).
Transfections and transwell migration and invasion
analysis
To generate cells that stably expressed HS3ST2, 5 3 105
EOC cells were transfected with pcDNA3.1-HS3ST2-v5 or
pcDNA3.1/V5-His vector (Invitrogen) for migration and
invasion assays. The assays were performed as description in
the supplementary methods and materials (see supplementary
information).
Survival analysis
We used the Kaplan-Meier estimate and a Cox proportional
hazard model to conduct a survival analysis. The receiver
operating characteristic (ROC) curve was used to select the
optimal threshold of each CpG site and immunohistochemis-
try score. Bootstrapping was performed 200 times, and
default best methods were used to classify dead and alive
patients using the pROC package of R. We assigned the val-
ues higher than the threshold as “high” and those lower than
the threshold as “low”. Overall survival (OS) was defined as
the time between the first therapy and the end of follow up
or death due to epithelial ovarian cancer. The 5-year OS and
3-year OS were calculated the survival rate at a minimum
follow-up of 5 years and 3 years for alive patients, respec-
tively. Progression-free survival (PFS) was defined as the time
between the first therapy and the end of follow up or recur-
rence due to epithelial ovarian cancer. The log-rank test was
applied to compare different categories in the Kaplan-Meier
estimate. For the survival analysis based on the mRNA
expression of HS3ST2, IL-6, and various ligands, we used
the web tool KM plotter (http://kmplot.com/analysis/index.
php?p5service&cancer5ovar).29 We set the analyzed criteria
as OS, 5-year follow-up, and advanced-stage (31 4) in the
2015 version, and we excluded biased arrays and used the
auto select best cutoff. The output was in binary code speci-
fying the mRNA level of each gene as 1 or 0 for higher and
lower than the cutoff, respectively.
Statistical analysis
Data were analyzed by two-tailed statistical tests, and differ-
ences were considered statistically significant at P< 0.05. All
analyses were performed with R statistical software (version
3.1.2) or MedCalc version 17.4.4.
Data availability
The data that support the findings in this study are avail-
able. Methylomics of TSGH-dataset had deposited and
released in the GEO database with the accession code
GSE43265.
Results
Discovery of a differential DNA methylation profile with
prognostic significance
One hundred fifteen patients diagnosed with advanced-stage
EOC were included in the discovery set (n5 31) or the
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validation set (n5 84) to identify differentially methylated bio-
markers that predict disease outcome according to the REMARK
guidelines.30 The logistics of the present study are summarized
in Figure 1a. In the discovery phase, we analyzed the methylomic
profiles of the discovery set and filtered out 25 differentially
methylated genes related to patient outcome by dichotomization
of 3-year overall survival (OS, Fig. S1A, Supporting Informa-
tion). Analytic corroboration further selected 18 of 25 genes by
the union of two criteria (Figs. S1 and Table S3, Supporting
Information). The first criterion was the correlation between
DNA methylation status and OS by Cox regression analysis (Fig.
S1C, Supporting Information), and the second was the consis-
tency between gene expression and DNA methylation (Fig. S1D,
Supporting Information). Three genes were excluded because of
low CpG density (Fig. 1b). Fifteen of the 18 genes underwent
experimental verification of DNA methylation in three cancer
cell lines and one immortalized normal ovarian cell line by bisul-
fite pyrosequencing (Fig. 1c). Eight of the fifteen genes showed
low methylation in normal cells and high methylation in at least
one of three cancer cell lines; these genes were further tested in
tissues. Seven of the eight genes, ADRA1A, CD248, IGSF21,
HS3ST2, NEFH, POU4F2, and TWIST1, showed significant
differential methylation based on 3-year OS (Fig. 1d and Table
S4, Supporting Information).
Validation of the differential DNA methylation profile for
long-term survival
The prognostic significance of these seven genes was vali-
dated in an independent set of EOC patients from Tri-
Service General Hospital (TSGH set; n5 84). The methyla-
tion level of NEFH and HS3ST2 did not correlate with other
clinical variables such as age, grade, histological type,
subtype, debulking status, and drug resistance (Table S5,
Supporting Information); or progression-free survival (Table
S6, Supporting Information) but significantly correlated
with OS. The median 5-year OS was 28.8 and 30.3 months
in patients with high methylation of NEFH and HS3ST2,
respectively, compared to 48.0 and> 60 months in patients
with low methylation (P< 0.05, Figs. 2a and 2b). The haz-
ard ratio (HR) of high methylation was 2.37 (95% confi-
dence interval [CI]5 1.17 to 4.83) and 2.35 (95% CI5 1.07
to 5.14) for NEFH and HS3ST2, respectively (Table S6, Sup-
porting Information). Patients with high methylation of
NEFH and/or HS3ST2 had a median 5-year OS of 32.3
months, which was significantly worse than the> 60 months
for patients with low methylation of both genes (P5 0.028,
Fig. 2c). The adjusted HR for poor outcome was 4.0 (95%
CI5 1.53 to 10.47; P5 0.005, Table 1), suggesting that
DNA methylation is an independent prognostic factor. The
prognostic value of the NEFH/HS3ST2 methylation signa-
ture was confirmed in the TCGA and AOCS datasets
(P< 0.05, Figs. S2, 2d, and 2e; adjusted HR: 1.97 [95%
CI5 1.22 to 3.2] and 2.2 [95% CI5 1.24 to 3.88], respec-
tively; Table 1).
Prognostic significance of HS3ST2 gene and protein
expression
The functional relevance of HS3ST2 and NEFH DNA methyl-
ation to mRNA and protein expression was assessed. HS3ST2
and NEFH were re-expressed in EOC cells after treatment
with demethylation agents (Fig. S3, Supporting Information).
We further focused on HS3ST2 since high methylation of
HS3ST2 has been reported in many reproductive system can-
cers, such as cervical, endometrial and prostate cancer.31,32.
Using the TCGA and TSGH validation sets, we confirmed
the inverse correlation between mRNA and protein expres-
sion and DNA methylation (Fig. S4, Supporting Informa-
tion). Using a public database containing 1147 advanced-
stage EOC patients29, we confirmed that low HS3ST2 mRNA
expression was significantly correlated with poor 5-year OS
(Fig. 2f). The NEFH mRNA expression insignificantly corre-
lated with patients’ outcome (Fig. S5A, Supporting Informa-
tion). Low HS3ST2 protein expression was also significantly
associated with poor disease outcome, as evidenced by immu-
nohistochemical analysis of tissue microarrays (TMAs) (Figs.
2g and 2h). Taken together, high DNA methylation and low
HS3ST2 mRNA and protein expression are consistently
related to the poor outcome of patients with EOC. Interest-
ingly, the function of this heparan proteoglycan 3-O-sulfation
gene in cancer biology has been rarely investigated.32
HS3ST2 inhibits malignant phenotypes in ovarian cancer
HS3ST2 is responsible for adding a sulfate group to HS at
the 3-O position, the last step of HS modification. To eluci-
date the functional relevance of HS3ST2 in EOC prognosis,
we manipulated HS3ST2 expression in human EOC cells and
assessed the effects on malignant behaviors such as migra-
tion, invasion and proliferation. Endogenous HS3ST2 protein
expression was assessed in EOC cells (Fig. S6, Supporting
Information). We then established stable clones of SKOV3
cells that overexpressed HS3ST2 and transiently knocked
down HS3ST2 using shRNA in Kuramochi cells (Fig. 3a).
HS3ST2 expression significantly suppressed cell migration
and invasion (all P< 0.05), whereas knockdown of HS3ST2
significantly promoted cell migration and invasion (Figs. 3b
and 3c). HS3ST2 mildly inhibited cell proliferation (Fig. S7,
Supporting Information).
HS3ST2-mediated 3-O sulfation of HS interferes with
oncogenic signaling pathways
HS was reported to interfere with the binding of ligands,
such as FGF, EGF, and interleukins, to the appropriate
growth factor receptor or cytokine receptor.33 FGF2, EGF
and IL-6 signaling promotes tumorigenic behavior in EOC.
To determine whether HS3ST2-mediated 3-O sulfation affects
these oncogenic signaling pathways and the resulting pheno-
types, we investigated the phosphorylation status of down-
stream kinases after treatment with FGF2, EGF or IL-6.
HS3ST2 expression repressed STAT3 phosphorylation in
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Figure 1. Discovery and validation of prognosis-related gene methylation in ovarian cancer. (a) Logistics of the discovery and validation
pipelines. n, the number of genes. (b) In the experimental validation, we used two criteria to reduce the number of candidate genes. (c) DNA
methylation level of candidate genes in ovarian epithelial cell lines. IOSE: immortalized ovarian surface epithelial cells; Cp70, OVCAR3 and
SKOV3: cancer cell lines; IVD: in vitromethylated DNA from white blood cells; WBC: white blood cells from patients without a cancer history.
Each row contains CpG sites located in the promoter region of genes analyzed by bisulfite pyrosequencing. (d) DNA methylation levels of
candidate genes in ovarian cancer tissues. The methylation levels of each CpG site from a DNA pool containing 5 samples are shown as a pie
chart. The corresponding CpG site of each pie chart is shown in a stripe below. #, P<0.001 by logistic regression analysis (Table S4, Supporting
Information).
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response to IL-6 (Fig. 3d and Fig. S8, Supporting Informa-
tion) and, to a lesser extent, ERK phosphorylation after FGF2
and EGF stimulation (Fig. S9, Supporting Information) in a
dose-dependent manner. Downstream target genes of IL-6/
STAT3 signaling, including IL-1B, IL-6, IL-8, MMP1, and
MMP2, were all inhibited by HS3ST2 expression (Fig. 3e).
Figure 2. Disease outcome and survival analysis of patients with advanced-stage ovarian cancer related to NEFH/HS3ST2 DNA methylation
and HS3ST2 expression. (a) and (b), High methylation of NEFH and HS3ST2, respectively, was significantly related to worse five-year overall
survival (OS, P<0.05). (c), (d), and (e) High methylation of NEFH and/or HS3ST2 was related to a worse five-year OS in the TSGH, TCGA,
and AOCS datasets (P<0.05). The dotted lines indicate the median survival time. The low-risk presented low methylation of both NEFH/
HS3ST2. (f) HS3ST2 expression analysis showed that low mRNA levels were related to a worse five-year OS in an integrated dataset from
KM Plotter for ovarian cancer. (g) HS3ST2 protein levels were analyzed in the ovarian cancer tissue microarray (TMA) as dark brown
staining. Representative immunohistochemistry results include five advanced-stage ovarian cancers and a benign ovarian tumor (B-OvT).
Magnification: 3200. (h) Patients stratified by low HS3ST2 protein levels had a shorter OS. High DNA methylation, low mRNA level and low
protein level of HS3ST2 all significantly indicated a worse outcome of advanced-stage ovarian cancer patients.
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Figure 3. The effects of HS3ST2 expression and silencing on ovarian cancer cell migration and invasion and IL-6 stimulation. (a) HS3ST2
expression in SKOV3 and Kuramochi cells. The pcDNA3.1 control vector (VC) or vector encoding HS3ST2 cDNA (pcHS3ST2) was transfected
into SKOV3 cells. shRNA control (Ctrl shRNA) and HS3ST2 shRNA (shHS3ST2) were transiently transfected into Kuramochi cells. Transwell
migration (b) and invasion (c) assays showed reduced migration and invasion of cells with high HS3ST2 expression. * P<0.05, ** P<0.01, and
*** P<0.001 as determined by a one-tailed Student’s t test. (d) Decreased phospho-STAT3 (p-STAT3) levels following IL-6 treatment in cells
with high HS3ST2 expression were revealed by immunoblotting. (e) The suppression of IL-6 downstream targets was determined in untreated
and IL-6-treated cells with high HS3ST2 expression. HS3, pcHS3ST2. mRNA was harvested after IL-6 treatment for three hours. (f) Cells with high
HS3ST2 expression showed reduced migration and invasion in transwell assays following IL-6 treatment. ** P<0.01 and *** P<0.001 in (e)
and (f) as determined by a two-tailed Student’s t test. (g) Kaplan-Meier curves show the differences in 5-year OS of advanced-stage ovarian cancer
patients in an integrative transcriptomics dataset divided into four groups according to HS3ST2 and IL-6 expression. Patients with high IL-6
expression were stratified into significantly different curves according to HS3ST2 expression. The 5-year OS of patients with low HS3ST2 and high
IL-6 (red line) was lower than that of patients with high HS3ST2 and high IL-6 (gray line). The p values was calculated with the log-rank test. n,
number of cases; HR, hazard ratio with univariate Cox regression analysis; CI, confidence interval. All error bars represent the standard deviation.
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The basal levels of IL-1B IL-6, MMP1, and MMP2 were sig-
nificantly lower in HS3ST2-expressing cells than in vector
control cells, suggesting that autocrine or paracrine regulation
of these cytokines was affected by HS3ST2. Functional assays,
including migration and invasion assays, confirmed the
inhibitory effects of HS3ST2 in response to IL-6 (Fig. 3f).
Figure 4. Kaplan-Meier curve analysis of the five-year overall survival of ovarian cancer patients according to HS3ST2 expression and
different expression levels of heparan sulfate binding factors. The targets are heparan sulfate binding factors such as cytokines and growth
factors. The patients with low HS3ST2 and high Ligands (red lines) had a significantly worse outcome compared with patients with high
HS3ST2 and low Ligands (gray lines). The patients with high HS3ST2 and low targets (green lines) had a better outcome, except for the
curve depicting PDGFB. The hazard ratio (HR) of low EGF and low TGF-beta with low HS3ST2 is a significantly low risk (in blue line), 0.72
(0.58 to 0.91) and 0.8 (0.64 to 0.99), respectively. P values were calculated with the log-rank test for four groups. The HR was calculated
from the univariate Cox regression model. CI, conference interval.
Table 1. Cox regression analysis of risk factors for 5-year overall survival of patients with advanced ovarian cancer in three datasets
Dataset Variant1 Crude HR (95% CI) P Adjusted HR (95% CI) P
TSGH Low-risk 1 1
High-risk 2.43 (1.07 to 5.52) 0.034 4.0 (1.53 to 10.47)2 0.005
TCGA Low-risk 1 1
High-risk 2.09 (1.32 to 3.31) 0.002 1.97 (1.22 to 3.20)3 0.006
AOCS Low-risk 1 1
High-risk 2.13 (1.23 to 3.68) 0.006 2.20 (1.24 to 3.88)4 0.007
Abbreviations: HR, Hazard ratio; CI, confidence interval.
1The low-risk is low methylation of both genes.
2Adjusted for age, grade, histological type, and debulking status.
3Adjusted for age and debulking status.
4Adjusted for age. P<0.05 shows boldface and italic..
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Effects of HS3ST2 and oncogenic ligand expression on the
prognosis of ovarian cancer patients
Thus, HS sulfation status may interfere with oncogenic
ligand-receptor interactions and, therefore, affect cancer cell
behavior in the microenvironment. To test this hypothesis,
we analyzed HS3ST2 and IL-6 gene expression in relation to
prognosis using transcriptomics data from 1147 patients with
EOC.29 Patients with low HS3ST2 and high IL-6 expression,
the strongest oncogenic stimulus, had the lowest probability
of 5-year OS (Fig. 3g, red line, P5 0.005). The median sur-
vival of patients with low HS3ST2 and high IL-6
(HS3ST2L1IL-6H, red line in Fig. 3g) was 35.5 months (95%
CI5 28.0 to 45.0) compared to 50.7 months (95% CI5 41.6
to 60.0) for patients with HS3ST2H1IL-6L (green line in Fig.
3g and Table S7, Supporting Information), yielding a HR of
0.62 (95% CI5 0.46 to 0.84). IL-6 expression alone did not
significantly correlate with patient outcome (Fig. S5B,
Supporting Information). We also analyzed the expression of
HS3ST2 and a panel of HS-interacting oncogenic ligands in
relation to prognosis.34 Patients with HS3ST2L1LigandH (red
lines), in which the ligand was IL-5, EGF, FGF2, HBEGF,
PDGFB, or TGF-beta, had the shortest median survival (Fig.
4 and Fig. S10, Supporting Information). These results sup-
ported our hypothesis that 3-O sulfation of HS by HS3ST2
can interfere with the coupling of oncogenic ligands and
receptors and confers a differential outcome of EOC patients.
Taken together, we propose a model in which HS3ST2 is a
biomarker for targeted antibody therapies (Fig. 5). Ovarian
cancer cells without HS3ST2-mediated 3-O-sulfation of HS
have stronger ligand stimulation and oncogenic signaling
(Fig. 5a), and those with this modification have weaker
ligand stimulation and oncogenic signaling (Fig. 5b). Thera-
peutic antibodies or kinase inhibitors may work well in con-
ditions of low 3-O-sulfation of HS (Fig. 5c). Cancer cells with
high 3-O sulfation of HS may have intrinsic resistance to
oncogenic stimulation, rendering therapy ineffective (Fig. 5d).
Discussion
In this study, we successfully identified and validated a meth-
ylation signature, NEFH/HS3ST2, that stratifies a subgroup of
patients with poor survival. In addition, we showed for the
first time that 3-O sulfation of HS is detrimental to onco-
genic signaling, such as IL-6 and EGF signaling, which may
render useless current targeted therapies for ovarian cancer
without further patient stratification.
HS is a polysulfated glycosaminoglycan that consists of vari-
ably sulfated repeating polysaccharide units and attaches to
proteoglycan core proteins to form heparan sulfate proteogly-
can (HSPG); HS localizes to the cell surface and the extracellu-
lar matrix.34 Heparan sulfate-glucosamine sulfotransferases,
including HS6STs, HS2STs, and HS3STs, sequentially add sul-
fate groups at specific sites.35 There are seven isozymes of
human HS3STs that recognize different substrates for adding a
sulfate group at the 3-O of glucosamine of HS and result in
heavy-sulfated HS with a highly negative charge.32 Previous
studies reported that HSPG might act as a co-receptor to
enhance many cancer hallmark pathways by stabilizing ligand-
receptor complexes in carcinoma.34,36 However, different
lengths and variable sulfation of HS lead to structural heteroge-
neity, which may result in conflicting functional effects.37,38
Indeed, diverse structures of HS with different lengths and
modifications have distinct binding affinities for growth factors
and cytokines.35,38 Different isoforms of HS3STs also have con-
flicting functional effects.38 Methylation of HS3ST2 has been
reported in many types of cancer, but the effects of HS3ST2-
mediated sulfation of HS are rarely studied. HS3ST2 was
reported to suppress the migration, invasion and proliferation
of lung cancer cells and chondrosarcoma cells, but the mecha-
nisms were not elucidated.39,40 In contrast, HS3ST2 had the
opposite effect in breast cancer cells and increased cell inva-
sion.41 Syndecan-1 and syndecan-4 are HSPGs with three HS
moieties at the extracellular domain and show higher and
denser expression in ovarian carcinoma.42 Syndecan-1 regu-
lates the IL-6 and EGF signaling pathways in breast cancer.33,43
Figure 5. The hypothesis of therapeutic antibody responses in
ovarian cancer. Schematic of the effects of HS3ST2 on cytokines and
growth factors and different therapeutic antibody responses. (a) Cells
lacking HS3ST2-mediated 3-O-sulfation of HS of heparan sulfate pro-
teins (HSPG) have low ligand binding affinity and show active signal
transduction. (b) HS3ST2-mediated 3-O-sulfation of HS creates a
high ligand binding affinity and triggers weak signal transduction. (c)
Therapeutic antibodies might be highly antagonistic to oncogenic
signaling in cancer cells without 3-O-sulfation of HS and might have
limited antagonistic activity in cancer cells with 3-O-sulfation of HS
(d).
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In endothelial cells, 3-O-sulfated HS inhibits VEGF signaling.38
Taken together, HS3ST2 modifies HS on HSPGs to fine tune
ligand-receptor interactions. Our study is the first to show that
HS3ST2 inhibits the malignant phenotypes of ovarian cancer
by disturbing various ligand-receptor signals, such as those
involving IL-6, FGF2 and EGF.
The tumor microenvironment is full of various growth fac-
tors and cytokines that impact mechano-coupling and affect
invasion.44 IL-6 is one of the major cytokines that promotes
migration, invasion, and angiogenesis of ovarian cancer.45,46
However, IL-6 mRNA expression failed to predict survival47
without consideration of HS3ST2 methylation or expression
status, supporting the clinical significance of HS sulfation. Most
therapeutic antibodies have failed in phase II/III clinical trials
due to the lack of biomarkers to identify the subset of patients
most likely to benefit from a specific targeted therapy. A few
studies have reported that cells compensate for the presence of
a neutralizing antibody by activating another oncogenic signal-
ing pathway.48,49 According to these reports, it is worth investi-
gating the targeting of multiple pathways with companion
biomarkers, such as targeting both VEGF and IL-6 or both
EGFR and IL-6. The present study showed that patients with
low HS3ST2 expression and high IL-6/EGF/FGF/VEGF expres-
sion had the worst outcomes. Epigenetic loss of HS3ST2 in
combination with higher expression of oncogenic cytokines or
growth factors may define a subset of ovarian cancer patients
who may benefit from targeted therapeutics.
Although epigenetic therapy is promising, there is a need for
biomarkers for the non-specific demethylation agents used to
treat solid tumors. A phase II study failed to establish methyl-
ated hMLH1 as a good companion biomarker for decitabine
and carboplatin treatment in ovarian cancer.8 The prognostic
significance of NEFH/HS3ST2 methylation was validated in
three independent datasets, the TSGH, AOCS, and TCGA data-
sets. Indeed, in a patient-derived ovarian cancer xenograft
study, decitabine treatment resulted in demethylation of NEFH
and HS3ST2 (Fig. S11, Supporting Information).50 The NEFH/
HS3ST2 methylation signature may be helpful for stratifying
heterogeneous ovarian cancer patients for epigenetic therapies.
There are limitations in the present study. Although the down-
stream signals of IL-6 or RTKs were affected after expression or
knockdown of HS3ST2, direct evidence of sulfation changes on
proteoglycan is still lacking. The application of NEFH/HS3ST2
methylation as companion diagnostics for target or epigenetic
therapies warrants further investigations.
In summary, using an epigenomics approach, we identi-
fied NEFH/HS3ST2 methylation as a prognostic biomarker
for ovarian cancer patients. HS3ST2 methylation can modu-
late oncogenic ligand-receptor interactions and thus serve as
a biomarker for precision medicine in ovarian cancer.
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